Date: 2019-09-13
Type of information: Nomination
Compound: CEO
Company: Gemini Therapeutics (USA)
Therapeutic area: Rare diseases - Genetic diseases- Ophthalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On September 13, 2019, Gemini Therapeutics, a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders, announced the appointment of Jason Meyenburg, MBA, as Chief Executive Officer (CEO). Mr. Meyenburg will also join the company’s Board of Directors. Mr. Meyenburg joins Gemini from Orchard Therapeutics, where he previously served as Chief Commercial Officer.During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GlaxoSmithKline and launched an IPO in 2019. Before Orchard, Mr. Meyenburg was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, he spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas.
Financial terms:
Latest news:
